Linked Life Data

2903827

Source:http://linkedlifedata.com/resource/pubmed/id/2903827

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1989-1-12
pubmed:abstractText
The pharmacokinetics of xamoterol, a beta-adrenergic partial agonist under clinical evaluation for the treatment of mild to moderate heart failure, have been studied in 8 cardiac failure patients (NYHA Class II) of mean age 62 years. After i.v. dosing, the elimination half-life was 7.4 +/- 0.4 h, the total body clearance was 228 +/- 30 ml.min-1 and the volume of distribution at steady-state was 56 +/- 9 l. 72.5 +/- 4.3% of the dose was recovered unchanged in urine. After the oral dose, the absolute bioavailability of xamoterol was shown to be 5.9%. Peak plasma concentrations occurred 1 to 2.5 h after the oral dose. The apparent elimination half-life was significantly longer after oral doses (16 +/- 2 h) compared to that observed after an intravenous dose. Renal clearance of xamoterol exceeded glomerular filtration rate as measured by creatinine clearance. The pharmacokinetics of xamoterol in cardiac failure patients with good renal function (creatinine clearance greater than 90 ml.min-1) were similar to published data in young healthy male volunteers.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0031-6970
pubmed:author
pubmed:issnType
Print
pubmed:volume
35
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
183-5
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Pharmacokinetics of xamoterol after intravenous and oral administration to patients with chronic heart failure.
pubmed:affiliation
Department of Internal Medicine and Cardiology, University of Arhus, Denmark.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial